Literature DB >> 14691052

Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins.

David Alonso-Escolano1, Alex Y Strongin, Ada W Chung, Elena I Deryugina, Marek W Radomski.   

Abstract

1. Matrix metalloproteinase-2 (MMP-2) plays a role in agonist- and tumour cell-induced platelet aggregation (TCIPA). 2. MMP-2 is synthesized as a proenzyme and is activated at the cell surface by membrane type-1 matrix metalloproteinase (MT1-MMP, MMP-14). 3. The significance of tumour cell-associated MT1-MMP for TCIPA was investigated using human breast carcinoma MCF7 cells stably coexpressing the integrin alphavbeta3 with MT1-MMP, cells expressing alphavbeta3 alone and mock-transfected cells. 4. Western blot and zymography confirmed that alphavbeta3/MT1-MMP cells expressed MT1-MMP and efficiently processed proMMP-2 to MMP-2. 5. Aggregometry, phase-contrast and transmission electron microscopy and flow cytometry were used to characterize TCIPA induced by MCF7 cell lines. 6. The aggregating potency of cells was: alphavbeta3/MT1-MMP >alphavbeta3=mock cells, as shown by aggregometry and phase-contrast microscopy. 7. Electron microscopy revealed close, membrane-membrane interactions between activated platelets and alphavbeta3/MT1-MMP cells during TCIPA. 8. Inhibition of MMP-2 with the neutralizing anti-MMP-2 antibody (5 microg ml(-1)) and o-phenanthroline (100 microm) reduced aggregation induced by alphavbeta3/MT1-MMP cells. 9. TCIPA induced by alphavbeta3/MT1-MMP cells was also reduced by inhibiting the generation and actions of ADP with apyrase (250 microg ml(-1)) and 2-methylthio-AMP (2-MeSAMP) (30 microm), but not N(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate (MRS2179) (30 microm). 10. Flow cytometry demonstrated that TCIPA enhanced expression of glycoprotein (GP) Ib and IIb/IIIa receptors not only on platelets but also on breast cancer cells. 11. Thus, (a) human breast carcinoma cell surface-associated MT1-MMP, via activating proMMP-2, stimulates TCIPA; (b) ADP amplifies the effects of MMPs via stimulation of P2Y(12) receptors and (c) both tumour- and platelet-derived GPIb and GPIIb/IIIa are involved in the aggregatory effects of MT1-MMP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691052      PMCID: PMC1574193          DOI: 10.1038/sj.bjp.0705606

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

Review 1.  Structure and function of von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIbbeta 3 activation both in platelets and a transfected Chinese hamster ovary cell system.

Authors:  Y Zaffran; S C Meyer; E Negrescu; K B Reddy; J E Fox
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

3.  Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.

Authors:  A Baurand; P Raboisson; M Freund; C Léon; J P Cazenave; J J Bourguignon; C Gachet
Journal:  Eur J Pharmacol       Date:  2001-02-02       Impact factor: 4.432

4.  Human prostate carcinoma cells express functional alphaIIb(beta)3 integrin.

Authors:  M Trikha; J Timar; S K Lundy; K Szekeres; K Tang; D Grignon; A T Porter; K V Honn
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

5.  Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.

Authors:  P Jurasz; G Sawicki; M Duszyk; J Sawicka; C Miranda; I Mayers; M W Radomski
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

6.  MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

Authors:  A Talvensaari-Mattila; P Pääkkö; T Turpeenniemi-Hujanen
Journal:  Breast Cancer Res Treat       Date:  1999-12       Impact factor: 4.872

7.  Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation.

Authors:  I Kazes; I Elalamy; J D Sraer; M Hatmi; G Nguyen
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase.

Authors:  E I Deryugina; M A Bourdon; K Jungwirth; J W Smith; A Y Strongin
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

9.  Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3.

Authors:  K Hotary; E Allen; A Punturieri; I Yana; S J Weiss
Journal:  J Cell Biol       Date:  2000-06-12       Impact factor: 10.539

10.  Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5.

Authors:  N Koshikawa; G Giannelli; V Cirulli; K Miyazaki; V Quaranta
Journal:  J Cell Biol       Date:  2000-02-07       Impact factor: 10.539

View more
  37 in total

1.  Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap.

Authors:  D Bazou; M J Santos-Martinez; C Medina; M W Radomski
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

2.  Nanoparticle-induced platelet aggregation and vascular thrombosis.

Authors:  Anna Radomski; Paul Jurasz; David Alonso-Escolano; Magdalena Drews; Maria Morandi; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

3.  Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Garth W Tormoen; Todd H Wagner; Parag Mallick; Owen J T McCarty
Journal:  Converg Sci Phys Oncol       Date:  2017-05-17

4.  Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.

Authors:  Carlos Medina; Shona Harmon; Iwona Inkielewicz; Maria Jose Santos-Martinez; Michael Jones; Paula Cantwell; Despina Bazou; Mark Ledwidge; Marek W Radomski; John F Gilmer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.

Authors:  Elisabeth M Battinelli; Beth A Markens; Joseph E Italiano
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

6.  Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases.

Authors:  Ada W Y Chung; Anna Radomski; David Alonso-Escolano; Paul Jurasz; Michael W Stewart; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2004-11-08       Impact factor: 8.739

Review 7.  Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.

Authors:  Luise Erpenbeck; Michael P Schön
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

8.  Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.

Authors:  C E Holmes; J E Levis; D L Ornstein
Journal:  Clin Exp Metastasis       Date:  2009-05-15       Impact factor: 5.150

9.  Living in shear: platelets protect cancer cells from shear induced damage.

Authors:  Karl Egan; Niamh Cooke; Dermot Kenny
Journal:  Clin Exp Metastasis       Date:  2014-06-19       Impact factor: 5.150

10.  Role of ADP receptors on platelets in the growth of ovarian cancer.

Authors:  Min Soon Cho; Kyunghee Noh; Monika Haemmerle; Dan Li; Hyun Park; Qianghua Hu; Takeshi Hisamatsu; Takashi Mitamura; Sze Ling Celia Mak; Satya Kunapuli; Qing Ma; Anil K Sood; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2017-07-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.